Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Mitochondrial pyruvate carrier 1-like protein (MPC1L) is a small mitochondrial inner membrane transporter. In humans, it forms a heterodimer with the protein MPC2, creating a functional pyruvate transporter in the testes. This complex facilitates the crucial step of shuttling pyruvate from glycolysis across the mitochondrial inner membrane to the matrix, where it feeds into the tricarboxylic acid (TCA) cycle for oxidative phosphorylation and ATP production. MPC1L shares about 64% identity with the broadly expressed MPC1 and is highly tissue-specific. Structural studies show the complex operates as an alternating access transporter, utilizing specific amino acid residues for pyruvate binding and transport in a pH-dependent mechanism. The MPC complex is of pharmacological interest as a therapeutic target for metabolic diseases and some cancers, with several small molecule inhibitors developed to modulate its activity
Competitive inhibition of pyruvate transport (drugs bind at the substrate recognition site, blocking pyruvate access)
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Mitochondrial pyruvate carrier 1-like protein (MPC1L).